Article Text

PDF
Treatment of ocular squamous cell carcinomas in cattle with interleukin-2
  1. R. J. E. Stewart, BVSc, MVSc1,
  2. F. W. G. Hill, PhD, DSc, MRCVS2,
  3. A. Masztalerz, MSc, PhD3,
  4. J. J. L. Jacobs, MSc, PhD5,
  5. J. W. Koten, MD, PhD4 and
  6. W. Den Otter, MSc, PhD4
  1. 1 Faculty of Veterinary Science, University of Zimbabwe, PO Box MP167, Mount Pleasant, Harare, Zimbabwe
  2. 2 Faculty of Medicine, University of Zimbabwe, PO Box MP167, Mount Pleasant, Harare, Zimbabwe
  3. 3 Department of Cell Biology and Histology, Faculty of Veterinary Medicine, Utrecht University PO Box 80.158, 3508 TD Utrecht, The Netherlands
  4. 4 Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University PO Box 80.158, 3508 TD Utrecht, The Netherlands
  5. 5 AmCOGG Research Institute Amsterdam Centre for Health and Health Care Research, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

Abstract

In total, 174 bovine ocular squamous cell carcinomas of varying sizes (20 to 2800 mm2 in area) were treated daily with peritumoural injections of solvent, or solvent containing 5000 U, 20,000 U, 200,000 U, 500,000 U, 1 million U or 2 million U interleukin-2 (il-2) for 10 days. The tumours were measured and clinically staged before treatment and at one, three, four, nine and 20 months after treatment. After 20 months, 14 per cent of the tumours treated with the solvent had regressed completely, a significantly smaller proportion than the 55 per cent treated with 5000 U il-2, 52 per cent treated with 20,000 U il-2, 58 per cent treated with 200,000 U il-2, 50 per cent treated with 500,000 U il-2, 69 per cent of tumours treated with 1 million U il-2, 52 per cent treated with 2 million U il-2. The tumours on the third eyelid and limbus were the most responsive.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.